MP12-01 CONSISTENT BIOPSY QUALITY AND GLEASON GRADING WITHIN THE GLOBAL ACTIVE SURVEILLANCE GLOBAL ACTION PLAN 3 INITIATIVE: A PREREQUISITE FOR FUTURE STUDIES

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance I1 Apr 2018MP12-01 CONSISTENT BIOPSY QUALITY AND GLEASON GRADING WITHIN THE GLOBAL ACTIVE SURVEILLANCE GLOBAL ACTION PLAN 3 INITIATIVE: A PREREQUISITE FOR FUTURE STUDIES Theo van der Kwast, Sophie Bruinsma, Daan Nieboer, Jozien Helleman, Monigue Roobol, and The Movember Foundation’s GAP3 consortium Theo van der KwastTheo van der Kwast More articles by this author , Sophie BruinsmaSophie Bruinsma More articles by this author , Daan NieboerDaan Nieboer More articles by this author , Jozien HellemanJozien Helleman More articles by this author , Monigue RoobolMonigue Roobol More articles by this author , and The Movember Foundation’s GAP3 consortium More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.388AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Within the Movember Foundation′s Global Action Plan focused on Prostate Cancer Active Surveillance (GAP3), 25 centers across the globe collaborate to reach consensus on inclusion criteria, surveillance schedules and intervention thresholds for active surveillance (AS) of men with low risk prostate cancer (PCa). To this end, a centralized PCa AS database was created comprising data on more than 15,000 patients worldwide. Here comparability of the histopathology from different cohorts in terms of biopsy quality and Gleason grading was assessed. METHODS A centralized pathology review of 445 biopsies (5-10% randomly selected biopsies from 15 of the GAP3 centers) was performed by an experienced pathologist. These biopsies were reported over a timespan of more than 20 years. ISUP grade groups (GG), cribriform and/or intraductal carcinoma (CR/IDC) and biopsy core lengths measured on the glass slides were recorded. RESULTS Discrepant biopsy GG at review were found in 48 cases (11%), which is comparable to rates between 10-20% previously reported in literature. Frequency of discrepant GG was below 20% for 11 of the 15 centers (Figure 1a). Upgrading from GG1 to GG≥2 occurred in 20 biopsies and downgrading from GG≥2 to GG1 in 28 biopsies. The average biopsy core length was similar among the analyzed cohorts (Figure 1b). We observed CR/IDC in 7/377 biopsies originally reported as GG1 (1.8%), which is slightly more often than seen in contemporary GG1 biopsies according to literature (0.8%)1. CR/IDC was observed in 16 of 445 assessed biopsies (3.6%). Upgrading at review from GG1 to GG≥2 occurred in 5/16 biopsies showing CR/IDC (31%) and downgrading from GG≥2 to GG1 in 1 biopsy (6%). CONCLUSIONS This centralized pathology review of prostate biopsies from the multi center GAP3 initiative revealed an acceptable discrepancy rate for GG and similar overall biopsy core quality among the 15 GAP3 centers. The increased frequency of CR/IDC in GG1 biopsies may be attributed to modifications in Gleason grading over time, since in reviewed GG1 biopsies CR/IDC frequency was at the same low level as published in literature. The observed consistency in biopsy quality and grading will enable further data analyses without correction towards uniform global guidelines for active surveillance of men with low risk prostate cancer. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e135 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Theo van der Kwast More articles by this author Sophie Bruinsma More articles by this author Daan Nieboer More articles by this author Jozien Helleman More articles by this author Monigue Roobol More articles by this author The Movember Foundation’s GAP3 consortium More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...